Company intelligence / Profile preview

Nanolive

Tolochenaz, Vaud, Switzerlandnanolive.com ↗

Ownership: Private
Development stage: Other

Overview

Nanolive’s platforms enable label-free, non-invasive live cell imaging and digital analysis for research in drug discovery, immuno-oncology, neuroscience, mitochondrial biology, and regenerative medicine. Their technology allows real-time observation of living cells in three dimensions without damaging them. The company’s products are used by leading biopharma companies to accelerate discovery workflows but do not themselves generate clinical results as they are research tools rather than therapeutics.

Modalities: DeviceDigital assay platform
Industry: Non-Drug Biotech

Partnerships

Collaborates with leading biopharma companies and academic institutions for deployment of its technologies

Beyond the preview

Go deeper on Nanolive.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanolive.

Explore the full profile